The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
about
Applications of CYP450 testing in the clinical settingDevelopments in renal pharmacogenomics and applications in chronic kidney diseaseCYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle.Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future.Antihypertensive therapy: special focus on drug interactions.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Cytochrome p450 enzymes and cardiovascular disease.Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.Effects of Losartan and Amlodipine on Left Ventricular Remodeling and Function in Young Stroke-Prone Spontaneously Hypertensive Rats.Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.Progress toward genetic tailoring of heart failure therapyModulation of cardiac cytochrome P450 in patients with heart failure.The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine
P2860
Q24621760-0A818806-9585-4590-A43F-27D5043797A8Q26999279-A46AFD0C-8E04-4B10-9881-40F3B52D629CQ33984240-AA6C2189-AB93-4CED-BD0A-E6CDE404F824Q35109802-F2D00AD7-3E98-41B4-B1BA-95FF40A90499Q35116095-ECFEE93C-425D-400F-8B26-3F540CF29987Q35570981-CF529DFB-9E29-4047-8DAE-DC1942FABFD3Q35594567-7861DB11-2496-49D1-9A7C-20D0B244DC80Q35661209-3C3B93B2-86A9-4092-ADB7-E50B869A8011Q36006519-8A507111-1915-4B0B-8D50-137D4F16C53DQ36285918-831081EF-60CF-4CFD-8FCF-21A5B10C5866Q36441503-6BC44584-7C78-4C22-A64E-116B6CAB6EE3Q36487290-0AAF5005-3952-465E-B81D-98E8460134CFQ36489410-2ACF167D-5810-4216-BB5E-0A63B5EA0BA0Q36721831-77D0FDEB-A1C8-4D13-9731-51C8E8DEF01AQ37671280-65094D84-1F76-4713-A6CD-45F581811421Q37762496-99032933-B793-4FAD-9D7A-4C86FDD91D35Q38175461-0030E043-2D00-4A4F-BACE-D56F3ED5ED04Q39456476-3E6128D5-90AC-47D0-8861-47BE725D5E52Q42701736-AC4653A3-5102-4A10-B350-87880D3EB60BQ44930351-E1BF9D59-207C-4EC7-9A4B-B5481E387846Q47570862-FF89D978-62B6-4BDF-912A-F9F51860CC1CQ57995102-0C8DDB2A-EF41-43BF-9379-3046696A8710
P2860
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The CYP2C9 genotype predicts t ...... n vs Atenolol (SILVHIA) trial.
@en
The CYP2C9 genotype predicts t ...... ophy Investigation vs Atenolol
@nl
type
label
The CYP2C9 genotype predicts t ...... n vs Atenolol (SILVHIA) trial.
@en
The CYP2C9 genotype predicts t ...... ophy Investigation vs Atenolol
@nl
prefLabel
The CYP2C9 genotype predicts t ...... n vs Atenolol (SILVHIA) trial.
@en
The CYP2C9 genotype predicts t ...... ophy Investigation vs Atenolol
@nl
P2093
P50
P1476
The CYP2C9 genotype predicts t ...... on vs Atenolol (SILVHIA) trial
@en
P2093
Håkan Melhus
Julia Karlsson
K Peter Ohman
Karin Malmqvist
Lisa Kurland
P304
P356
10.1097/00004872-200210000-00030
P577
2002-10-01T00:00:00Z